Louis Kuritzky, MD
Clinical Assistant Professor Emeritus
University of Florida
Disclosure: Louis Kuritzky, MD has no financial information to disclose.
Seth S. Martin, MD, MHS
Director, Lipid Clinic
Division of Cardiology
Department of Medicine
Johns Hopkins Hospital
Disclosure: Seth S. Martin, MD, MHS
Spouse employment role: Pharmacist at Walgreens
Alan Brown, MD, FACC, FAHA, FNLA, FASPC
Director, Division of Cardiology
Advocate Lutheran General Hospital
Park Ridge, Illinois
Co-Director, Cardiology Service Line
Advocate Medical Group
Park Ridge, Illinois
Clinical Associate Professor
Loyola Stritch School of Medicine
Disclosure: Alan Brown, MD, FACC, FAHA, FNLA, FASPC
Kathleen H. Byrne, MSN, CRNP, FPCNA
Cardiovascular Nurse Practitioner
Johns Hopkins University
Advanced Lipid Disorders Clinic
Disclosure: Kathleen H. Byrne, MSN, CRNP, FPCNA has no financial information to disclose.
The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests.
“Optimal Lipid Management for Primary Care Practitioners: An Update on PCSK9 Inhibitors: A Medical Crossfire® Activity” is designed to update primary care providers and other health care professionals on the evolving landscape of lipid-lowering therapy. During this Medical Crossfire®, expert faculty, including a lipidologist, cardiologist, primary care physician, and allied health care professional, will engage in a multidisciplinary roundtable discussion to discuss how to best optimize and individualize hypercholesterolemia management with newer therapies.
This CME activity is primarily intended for community clinicians, primary care clinicians, and cardiologists, as well as other professionals who treat patients with hyperlipidemia. These HCPs are in positions to educate patients and guide treatment decisions.
Upon completion of this CME activity, you should be better prepared to:
Describe the latest guidelines and recommendations on cholesterol management from major clinical organizations.
Discuss potential cholesterol-lowering therapies beyond statins and explain when these nonstatin therapies should be considered.
Summarize in detail the indications for proprotein convertase subtilisin kexin type 9 inhibitor (PCSK9i) therapy.
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians, and is a provider approved by the California Board of Registered Nursing (CBRN).
Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™ and for 1.5 contact hours for nurses. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All other health care professionals completing this course will be issued a statement of participation.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Amgen.
This activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to the diagnostic, treatment, and management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Community Practice Connections™: New Frontiers in Immuno-Oncology for Microsatellite Instability-High Cancers
Aug 29, 2018
Aug 31, 2018